Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $6.25

by · The Markets Daily

GoodRx (NASDAQ:GDRX – Free Report) had its price target trimmed by Citigroup from $7.00 to $6.25 in a report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on GDRX. KeyCorp decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Morgan Stanley reduced their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Finally, Mizuho started coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, GoodRx currently has a consensus rating of “Moderate Buy” and an average price target of $8.38.

Check Out Our Latest Analysis on GoodRx

GoodRx Stock Performance

NASDAQ:GDRX opened at $4.55 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a 50-day moving average of $4.72 and a two-hundred day moving average of $6.57. The stock has a market cap of $1.73 billion, a P/E ratio of -151.67, a PEG ratio of 3.43 and a beta of 1.27. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26.

Hedge Funds Weigh In On GoodRx

A number of large investors have recently bought and sold shares of GDRX. American Century Companies Inc. bought a new position in GoodRx in the second quarter worth about $18,183,000. Point72 Asset Management L.P. acquired a new stake in shares of GoodRx in the third quarter valued at approximately $11,295,000. Rubric Capital Management LP increased its stake in shares of GoodRx by 76.5% in the second quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock valued at $29,147,000 after purchasing an additional 1,619,748 shares during the period. Millennium Management LLC increased its stake in shares of GoodRx by 36.5% in the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after purchasing an additional 1,102,758 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of GoodRx in the third quarter valued at approximately $5,675,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

See Also